UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT ~~Pursuant to Section 13 or 15(d) of the~~

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of ~~earliest~~Earliest ~~event~~Event ~~reported~~Reported): June 1527, 2018

ANTHERA PHARMACEUTICALS, INC.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Charter~~its charter)

Delaware	001-34637	20-1852016	~~20-1852016~~
(State or Other Jurisdiction of Incorporation)	(Commission File Number)		(I.R.S. Employer Identification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
25801 Industrial Boulevard, Suite B, Hayward, California		94545
(Address of Principal Executive Offices)		(Zip Code)

25801 Industrial Boulevard, Suite B, Hayward, California		94545
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (510) 856-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 53.~~02 Departure~~01. Notice of ~~Directors~~Delisting or ~~Certain~~Failure ~~Officers;~~to ~~Election~~Satisfy ofa ~~Directors;~~Continued ~~Appointment~~Listing ofRule ~~Certain~~or ~~Officers~~Standard; ~~Compensatory~~Transfer ~~Arrangements~~ of ~~Certain Officers~~Listing.

On June 1527, 2018, Anthera Pharmaceuticals, Inc. (the “Company”) ~~and~~announced ~~Craig~~that ~~Thompson~~it ~~entered~~has ~~into~~withdrawn aits ~~letter~~request ~~agreement~~for ~~(the~~a ~~“Letter~~hearing ~~Agreement”)~~to ~~amending~~appeal ~~Mr.~~the ~~Thompson’s~~determination ~~Amended~~of ~~and Restated Employment Agreement with~~ the ~~Company~~Staff ~~dated~~of ~~January~~The 5,Nasdaq ~~2018~~Stock ~~(the~~Market (“~~Employment Agreement~~Nasdaq”). ~~Pursuant~~ to ~~the~~delist ~~terms of~~ the ~~Letter~~Company’s ~~Agreement,~~securities ~~Mr. Thompson acknowledged and agreed that, among other things, (i)~~ from ~~June~~The ~~15,~~Nasdaq ~~2018~~Capital ~~through~~Market. ~~June~~Nasdaq ~~30,~~has ~~2018~~informed (the ~~“Transition~~Company ~~Period”),~~that heit ~~shall~~will ~~only~~suspend ~~be required to devote 20% of his working time and efforts to~~ the ~~business~~trading ~~and affairs~~ of the Company,’s ~~(ii)~~securities ~~during~~at the ~~Transition~~open ~~Period~~of hebusiness ~~shall~~on ~~receive~~June an28, ~~annualized~~2018 ~~base~~as ~~salary~~a inresult ~~the amount~~ of ~~$92,000,~~the ~~provided~~Company’s ~~that~~failure ~~for~~to ~~purposes~~meet ofthe ~~his~~minimum ~~severance~~bid ~~eligibility~~price asrequirement ~~set~~pursuant ~~forth~~to inListing ~~Section~~Rule 5550(ba)(2), ofand the ~~Employment~~Company’s ~~Agreement,~~disclosure ~~his~~on ~~“Base~~its ~~Salary”~~most ~~shall~~recent beform ~~based~~10-Q onfor ~~his~~the ~~full~~quarter ~~salary~~ended ofMarch ~~$460~~31,~~000,~~ ~~and~~2018 ~~(iii)~~in ~~his~~which ~~employment with~~ the Company ~~shall~~has ~~end~~disclosed ~~effective as of June 30, 2018. The parties agreed~~ that ~~such~~it ~~separation~~has ofsuspended ~~employment~~all ~~shall~~clinical bedevelopment ~~deemed~~activities ~~a “Termination without Cause,”~~ and, ~~subject~~commenced toa ~~the~~wind ~~terms~~down of ~~his~~its ~~Employment Agreement, Mr~~operation. ~~Thompson~~Nasdaq ~~shall~~will bealso ~~entitled~~file toa ~~receive~~Form ~~severance~~25 ~~benefits~~with ~~set~~the ~~forth~~Securities inand ~~Section~~Exchange 5Commission (bthe “SEC”) ofafter ~~the~~applicable ~~Employment~~appeal ~~Agreement~~periods ~~subject~~have lapsed to ~~his~~notify ~~execution~~the ~~and~~SEC ~~non-revocation~~ of athe ~~separation~~delisting ~~and~~of ~~release agreement and continued compliance with his contractual obligations to~~ the Company.’s ~~Mr.~~securities ~~Thompson~~from ~~will~~The ~~continue~~Nasdaq toCapital ~~serve~~Market. asThe ~~President,~~foregoing ~~Chief~~disclosure ~~Executive~~is ~~Officer,~~in asaccordance awith ~~director~~subsection on(d) ~~the Company’s Board~~ of ~~Directors,~~item ~~and~~3.01 ~~provide consulting services to the Company after the termination~~ of ~~his~~Form ~~Employment Agreement~~8-K.

The ~~foregoing~~Company ~~summary~~expects ofthat ~~the~~its ~~Letter~~common ~~Agreement~~stock ~~does~~will ~~not~~be ~~purport~~eligible tofor betrading ~~complete~~on ~~and~~the isOTC ~~subject to~~Market, ~~and~~an ~~qualified~~electronic inquotation ~~its~~service ~~entirety~~maintained by, the ~~full~~Financial ~~text~~Industry ofRegulatory ~~the~~Authority, ~~Letter~~effective ~~Agreement,~~with athe ~~copy~~open of ~~which~~business ison ~~filed~~June as28, ~~Exhibit 10~~2018.1 toThe ~~this~~Company’s ~~Current~~shares ~~Report~~are ~~and~~expected isto ~~incorporated~~continue ~~herein~~to bytrade ~~reference~~under the symbol ANTH.

Item 97.01 Regulation ~~Financial~~FD ~~Statements and Exhibits~~Disclosure.

~~Exhibit~~On ~~10.1~~June ~~Letter~~27, ~~Agreement~~2018, ~~between~~the ~~Anthera~~Company ~~Pharmaceuticals,~~issued ~~Inc.~~a ~~and~~press ~~Craig~~release ~~Thompson,~~announcing ~~dated~~that effective at the open of business on June 1528, 2018, the Company’s common stock will be delisted from The Nasdaq Capital Market. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Press Release, dated June 27, 2018, of Anthera Pharmaceuticals, Inc. (furnished herewith)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 18, 2018	Anthera Pharmaceuticals, Inc.
Date: June 27, 2018	Anthera Pharmaceuticals, Inc.
	By:	/s/ J. Craig Thompson
		J. Craig Thompson
		President and Chief Executive Officer
		President and CEO
		(Principal Executive Officer)

EXHIBIT INDEX

Exhibit No.	Description
10.1	Letter Agreement between Anthera Pharmaceuticals, Inc. and Craig Thompson, dated June 15, 2018.

Filing Compare · Anthera Pharmaceuticals Inc